{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:53:27Z","timestamp":1790182407533,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T00:00:00Z","timestamp":1566000000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Interv and Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s12928-019-00613-w","type":"journal-article","created":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T14:02:38Z","timestamp":1566050558000},"page":"250-258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Five-year clinical efficacy and safety of contemporary thin-strut biodegradable polymer versus durable polymer drug-eluting stents: a systematic review and meta-analysis of 9 randomized controlled trials"],"prefix":"10.1007","volume":"35","author":[{"given":"Tomoaki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Sotomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pannipa","family":"Suwannasom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Morino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Kozuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,17]]},"reference":[{"issue":"2","key":"613_CR1","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1161\/CIRCULATIONAHA.113.001790","volume":"129","author":"F Otsuka","year":"2014","unstructured":"Otsuka F, Vorpahl M, Nakano M, Foerst J, Newell JB, Sakakura K, Kutys R, Ladich E, Finn AV, Kolodgie FD, et al. Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014;129(2):211\u201323.","journal-title":"Circulation"},{"issue":"6","key":"613_CR2","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.jcin.2012.02.014","volume":"5","author":"SS Naidu","year":"2012","unstructured":"Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB, et al. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study. JACC Cardiovasc Interv. 2012;5(6):626\u201335.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"613_CR3","doi-asserted-by":"publisher","first-page":"14997","DOI":"10.1038\/s41598-017-14247-6","volume":"7","author":"P Lu","year":"2017","unstructured":"Lu P, Lu S, Li Y, Deng M, Wang Z, Mao X. A comparison of the main outcomes from BP-BES and DP-DES at five years of follow-up: a systematic review and meta-analysis. Sci Rep. 2017;7(1):14997.","journal-title":"Sci Rep"},{"issue":"9","key":"613_CR4","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1161\/CIRCULATIONAHA.111.058560","volume":"125","author":"L R\u00e4ber","year":"2012","unstructured":"R\u00e4ber L, Magro M, Stefanini GG, Kalesan B, van Domburg RT, Onuma Y, Wenaweser P, Daemen J, Meier B, J\u00fcni P, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents. Circulation. 2012;125(9):1110\u201321.","journal-title":"Circulation"},{"issue":"4","key":"613_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.jacc.2013.09.061","volume":"63","author":"T Palmerini","year":"2014","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabat\u00e9 M, Smits PC, Kaiser C, D\u2019Ascenzo F, Frati G, Mancone M, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents. J Am College Cardiol. 2014;63(4):299\u2013307.","journal-title":"J Am College Cardiol"},{"key":"613_CR6","doi-asserted-by":"publisher","first-page":"f6625","DOI":"10.1136\/bmj.f6625","volume":"347","author":"S Bangalore","year":"2013","unstructured":"Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, Faxon DP, Feit F. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347:f6625.","journal-title":"BMJ"},{"issue":"5","key":"613_CR7","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jcin.2016.12.002","volume":"10","author":"G El-Hayek","year":"2017","unstructured":"El-Hayek G, Bangalore S, Casso Dominguez A, Devireddy C, Jaber W, Kumar G, Mavromatis K, Tamis-Holland J, Samady H. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017;10(5):462\u201373.","journal-title":"JACC Cardiovasc Interv"},{"issue":"7109","key":"613_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629\u201334.","journal-title":"BMJ"},{"issue":"3","key":"613_CR9","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.114.012658","volume":"131","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, Yahagi K, Ladich E, Kutys R, Alexander R, Fowler D, Virmani R, Joner M. Hypersensitivity reaction in the US Food and Drug Administration-approved second-generation drug-eluting stents: histopathological assessment with ex vivo optical coherence tomography. Circulation. 2015;131(3):322\u20134.","journal-title":"Circulation"},{"issue":"6","key":"613_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1161\/01.CIR.0000116202.41966.D4","volume":"109","author":"R Virmani","year":"2004","unstructured":"Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004;109(6):701\u20135.","journal-title":"Circulation"},{"issue":"6","key":"613_CR11","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1002\/ccd.25993","volume":"86","author":"GJ Wilson","year":"2015","unstructured":"Wilson GJ, Marks A, Berg KJ, Eppihimer M, Sushkova N, Hawley SP, Robertson KA, Knapp D, Pennington DE, Chen YL, et al. The SYNERGY biodegradable polymer everolimus eluting coronary stent: Porcine vascular compatibility and polymer safety study. Catheter Cardiovasc Interv. 2015;86(6):E247\u201357.","journal-title":"Catheter Cardiovasc Interv"},{"issue":"10","key":"613_CR12","doi-asserted-by":"publisher","first-page":"e003803","DOI":"10.1161\/JAHA.116.003803","volume":"5","author":"G Nakazawa","year":"2016","unstructured":"Nakazawa G, Torii S, Ijichi T, Nagamatsu H, Ohno Y, Kurata F, Yoshikawa A, Nakano M, Shinozaki N, Yoshimachi F, et al. Comparison of vascular responses following new-generation biodegradable and durable polymer-based drug-eluting stent implantation in an atherosclerotic rabbit iliac artery model. J Am Heart Assoc. 2016;5(10):e003803.","journal-title":"J Am Heart Assoc"},{"key":"613_CR13","doi-asserted-by":"publisher","first-page":"f6530","DOI":"10.1136\/bmj.f6530","volume":"347","author":"EP Navarese","year":"2013","unstructured":"Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes DJ, Waksman R, Mauri L, Meredith IT, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530.","journal-title":"BMJ"},{"issue":"10","key":"613_CR14","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/eurheartj\/ehs086","volume":"33","author":"GG Stefanini","year":"2012","unstructured":"Stefanini GG, Byrne RA, Serruys PW, de Waha A, Meier B, Massberg S, Juni P, Schomig A, Windecker S, Kastrati A. Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4\u00a0years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. Eur Heart J. 2012;33(10):1214\u201322.","journal-title":"Eur Heart J"},{"issue":"5","key":"613_CR15","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jacc.2008.04.030","volume":"52","author":"M Joner","year":"2008","unstructured":"Joner M, Nakazawa G, Finn AV, Quee SC, Coleman L, Acampado E, Wilson PS, Skorija K, Cheng Q, Xu X, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52(5):333\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"613_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/nrcardio.2012.64","volume":"9","author":"F Otsuka","year":"2012","unstructured":"Otsuka F, Finn AV, Yazdani SK, Nakano M, Kolodgie FD, Virmani R. The importance of the endothelium in atherothrombosis and coronary stenting. Nat Rev Cardiol. 2012;9(8):439\u201353.","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"613_CR17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s12928-015-0341-5","volume":"31","author":"Y Mitsutake","year":"2016","unstructured":"Mitsutake Y, Ueno T, Ikeno F, Yokoyama S, Sasaki K, Nakayoshi T, Itaya N, Chibana H, Sasaki M, Fukumoto Y. Serial changes of coronary endothelial function and arterial healing after paclitaxel-eluting stent implantation. Cardiovasc Interv Ther. 2016;31(1):21\u20138.","journal-title":"Cardiovasc Interv Ther"},{"issue":"32","key":"613_CR18","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1093\/eurheartj\/ehv205","volume":"36","author":"F Otsuka","year":"2015","unstructured":"Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa E, Kastrati A, Virmani R, et al. Neoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment. Eur Heart J. 2015;36(32):2147\u201359.","journal-title":"Eur Heart J"},{"issue":"6","key":"613_CR19","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1253\/circj.CJ-14-0085","volume":"78","author":"Y Akazawa","year":"2014","unstructured":"Akazawa Y, Matsuo K, Ueda Y, Nishio M, Hirata A, Asai M, Nemoto T, Wada M, Murakami A, Kashiwase K, et al. Atherosclerotic change at 1\u00a0year after implantation of Endeavor zotarolimus-eluting stent vs. everolimus-eluting stent. Circ J. 2014;78(6):1428\u201336.","journal-title":"Circ J"},{"issue":"11","key":"613_CR20","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3760\/cma.j.issn.0366-6999.20133192","volume":"127","author":"Y Zhang","year":"2014","unstructured":"Zhang Y, Tian N, Dong S, Ye F, Li M, Bourantas CV, Iqbal J, Onuma Y, Muramatsu T, Diletti R, et al. Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. Chin Med J (Engl). 2014;127(11):2159\u201366.","journal-title":"Chin Med J (Engl)"},{"issue":"23","key":"613_CR21","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1016\/j.jcin.2017.06.059","volume":"10","author":"H Mori","year":"2017","unstructured":"Mori H, Cheng Q, Lutter C, Smith S, Guo L, Kutyna M, Torii S, Harari E, Acampado E, Joner M, et al. Endothelial barrier protein expression in biodegradable polymer sirolimus-eluting versus durable polymer everolimus-eluting metallic stents. JACC Cardiovasc Interv. 2017;10(23):2375\u201387.","journal-title":"JACC Cardiovasc Interv"},{"key":"613_CR22","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/CIRCULATIONAHA.118.034456","volume":"138","author":"S Bangalore","year":"2018","unstructured":"Bangalore S, Toklu B, Patel N, Feit F, Stone GW. Newer generation ultra-thin strut drug-eluting stents versus older second-generation thicker strut drug-eluting stents for coronary artery disease. Circulation. 2018;138:2216\u201326.","journal-title":"Circulation"},{"issue":"10","key":"613_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jcin.2018.04.014","volume":"11","author":"T Lefevre","year":"2018","unstructured":"Lefevre T, Haude M, Neumann FJ, Stangl K, Skurk C, Slagboom T, Sabate M, Goicolea J, Barragan P, Cook S, et al. Comparison of a novel biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: 5-year outcomes of the randomized BIOFLOW-II trial. JACC Cardiovasc Interv. 2018;11(10):995\u20131002.","journal-title":"JACC Cardiovasc Interv"},{"issue":"10149","key":"613_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0140-6736(18)31715-X","volume":"392","author":"T Pilgrim","year":"2018","unstructured":"Pilgrim T, Piccolo R, Heg D, Roffi M, Tuller D, Muller O, Moarof I, Siontis GCM, Cook S, Weilenmann D, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018;392(10149):737\u201346.","journal-title":"Lancet"},{"issue":"3","key":"613_CR25","doi-asserted-by":"publisher","first-page":"e343","DOI":"10.4244\/EIJ-D-18-00358","volume":"14","author":"W Wijns","year":"2018","unstructured":"Wijns W, Valdes-Chavarri M, Richardt G, Moreno R, Iniguez-Romo A, Barbato E, Carrie D, Ando K, Merkely B, Kornowski R, et al. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. EuroIntervention. 2018;14(3):e343\u201351.","journal-title":"EuroIntervention"},{"issue":"12","key":"613_CR26","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jcin.2017.02.029","volume":"10","author":"GJ Vlachojannis","year":"2017","unstructured":"Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vazquez N, Valdes M, Voudris V, Slagboom T, Goy JJ, den Heijer P, et al. Biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: final 5-year report from the COMPARE II trial (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent). JACC Cardiovasc Interv. 2017;10(12):1215\u201321.","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"613_CR27","doi-asserted-by":"publisher","first-page":"e2147","DOI":"10.4244\/EIJ-D-17-00230","volume":"13","author":"W Wijns","year":"2018","unstructured":"Wijns W, Vrolix M, Verheye S, Schoors D, Slagboom T, Gosselink M, Benit E, Kandzari D, Donohoe D, Ormiston JA. Long-term clinical outcomes of a crystalline sirolimus-eluting coronary stent with a fully bioabsorbable polymer coating: five-year outcomes from the DESSOLVE I and II trials. EuroIntervention. 2018;13(18):e2147\u201351.","journal-title":"EuroIntervention"},{"issue":"17","key":"613_CR28","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.4244\/EIJ-D-17-00529","volume":"13","author":"IT Meredith","year":"2018","unstructured":"Meredith IT, Verheye S, Dubois C, Dens J, Farah B, Carrie D, Walsh S, Oldroyd K, Varenne O, El-Jack S, et al. Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. EuroIntervention. 2018;13(17):2047\u201350.","journal-title":"EuroIntervention"},{"issue":"11 Supplement","key":"613_CR29","doi-asserted-by":"publisher","first-page":"A1018","DOI":"10.1016\/S0735-1097(18)31559-6","volume":"71","author":"R Jobe","year":"2018","unstructured":"Jobe R, Windecker S, Loli A, Mego D, Ando K, Muramatsu T, Stammen F, Curtis M, Helqvist S, Christen T, et al. Clinical outcomes to 4\u00a0years in patients implanted with bioabsorbable polymer synergy versus permanent polymer everolimus-eluting stents: the evolve ii randomized trial. J Am College Cardiol. 2018;71(11 Supplement):A1018.","journal-title":"J Am College Cardiol"},{"issue":"14","key":"613_CR30","first-page":"2561","volume":"127","author":"F Yuan","year":"2014","unstructured":"Yuan F, Chen X, Song X, Wang D, Zhang Z, Li W, Li Z, Li H, Chen X, Huo Y, et al. Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial. Chin Med J (Engl). 2014;127(14):2561\u20136.","journal-title":"Chin Med J (Engl)"},{"issue":"S1","key":"613_CR31","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/ccd.27465","volume":"91","author":"L Song","year":"2018","unstructured":"Song L, Li J, Guan C, Jing Q, Lu S, Yang L, Xu K, Yang Y, Xu B, Han Y, et al. Randomized comparison of novel biodegradable polymer and durable polymer-coated cobalt-chromium sirolimus-eluting stents: three-year outcomes of the I-LOVE-IT 2 trial. Catheter Cardiovasc Interv. 2018;91(S1):608\u201316.","journal-title":"Catheter Cardiovasc Interv"},{"key":"613_CR32","doi-asserted-by":"crossref","unstructured":"Kufner S, Joner M, Thannheimer A, Hoppmann P, Ibrahim T, Mayer K, Cassese S, Laugwitz K-L, Schunkert H, Kastrati A et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease: results from the ISAR-TEST 4 randomized trial. Circulation 2019;139(3):325\u201333.","DOI":"10.1161\/CIRCULATIONAHA.118.038065"},{"issue":"8","key":"613_CR33","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.jcin.2013.04.011","volume":"6","author":"PW Serruys","year":"2013","unstructured":"Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus eluted from A durable versus ERodable stent coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6(8):777\u201389.","journal-title":"JACC Cardiovasc Interv"},{"issue":"6","key":"613_CR34","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.5114\/aoms.2013.39793","volume":"9","author":"Q Li","year":"2013","unstructured":"Li Q, Tong Z, Wang L, Zhang J, Ge Y, Wang H, Li W, Xu L, Ni Z, Yang X. Efficacy and safety of a biodegradable polymer sirolimus-eluting stent in primary percutaneous coronary intervention: a randomized controlled trial. Arch Med Sci. 2013;9(6):1040\u20138.","journal-title":"Arch Med Sci"},{"issue":"7","key":"613_CR35","doi-asserted-by":"publisher","first-page":"815","DOI":"10.4244\/EIJ-D-17-01050","volume":"14","author":"M Natsuaki","year":"2018","unstructured":"Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Hanaoka KI, Tanabe K, Morino Y, et al. Five-year outcome of a randomised trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: the NOBORI biolimus-eluting versus XIENCE\/PROMUS everolimus-eluting stent trial (NEXT). EuroIntervention. 2018;14(7):815\u20138.","journal-title":"EuroIntervention"},{"issue":"5","key":"613_CR36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.4244\/EIJY14M12_13","volume":"11","author":"B Chevalier","year":"2015","unstructured":"Chevalier B, Wijns W, Silber S, Garcia E, Serra A, Paunovic D, Serruys P, investigators N. Five-year clinical outcome of the Nobori drug-eluting coronary stent system in the treatment of patients with coronary artery disease: final results of the NOBORI 1 trial. EuroIntervention. 2015;11(5):549\u201354.","journal-title":"EuroIntervention"},{"issue":"11","key":"613_CR37","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4244\/EIJ-D-17-00434","volume":"13","author":"L Jakobsen","year":"2017","unstructured":"Jakobsen L, Christiansen EH, Maeng M, Hansen KN, Kristensen SD, Botker HE, Terkelsen CJ, Jensen SE, Raungaard B, Madsen M, et al. Final five-year outcomes after implantation of biodegradable polymer-coated biolimus-eluting stents versus durable polymer-coated sirolimus-eluting stents. EuroIntervention. 2017;13(11):1336\u201344.","journal-title":"EuroIntervention"},{"issue":"3","key":"613_CR38","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jcin.2016.11.007","volume":"10","author":"B Raungaard","year":"2017","unstructured":"Raungaard B, Christiansen EH, Botker HE, Hansen HS, Ravkilde J, Thuesen L, Aaroe J, Villadsen AB, Terkelsen CJ, Krusell LR, et al. Comparison of durable-polymer zotarolimus-eluting and biodegradable-polymer biolimus-eluting coronary stents in patients with coronary artery disease: 3-year clinical outcomes in the randomized SORT OUT VI Trial. JACC Cardiovasc Interv. 2017;10(3):255\u201364.","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"613_CR39","first-page":"940","volume":"45","author":"CJ Li","year":"2017","unstructured":"Li CJ, Xu B, Guan CD, Gao RL, Investigators TA. Long term safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of coronary de novo lesions. Zhonghua Xin Xue Guan Bing Za Zhi. 2017;45(11):940\u20137.","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"issue":"38","key":"613_CR40","doi-asserted-by":"publisher","first-page":"e4820","DOI":"10.1097\/MD.0000000000004820","volume":"95","author":"H Zhang","year":"2016","unstructured":"Zhang H, Wang X, Deng W, Wang S, Ge J, Toft E. Randomized clinical trial comparing abluminal biodegradable polymer sirolimus-eluting stents with durable polymer sirolimus-eluting stents: nine months angiographic and 5-year clinical outcomes. Medicine (Baltimore). 2016;95(38):e4820.","journal-title":"Medicine (Baltimore)"}],"container-title":["Cardiovascular Intervention and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-019-00613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12928-019-00613-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12928-019-00613-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T04:05:52Z","timestamp":1721621152000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12928-019-00613-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,17]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["613"],"URL":"https:\/\/doi.org\/10.1007\/s12928-019-00613-w","relation":{},"ISSN":["1868-4300","1868-4297"],"issn-type":[{"value":"1868-4300","type":"print"},{"value":"1868-4297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,17]]},"assertion":[{"value":"9 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Y Sotomi, S. Nakatani, and Y. Higuchi received speaker honoraria from Abbott Vascular Japan, Boston Scientific Japan, TERUMO, Cardinal Health, and Medtronic. Y. Morino received research grant from Boston Scientific Japan and TERUMO, consultant fee from Japan Lifeline, and lecture fee from Abbott Vascular Japan and Medtronic. J. Ako received speaker honoraria from Abbott Vascular Japan, Boston Scientific Japan, TERUMO. K. Kozuma received speaker honoraria from Abbott Vascular Japan, Boston Scientific Japan, TERUMO and clinical search grant from Abbott Vascular Japan, TERUMO. Medtronic, and NIPRO. A. Hirayama reports grants and personal fees from Boston Scientific Japan, Abbott Vascular Japan, Japan Lifeline, and Medtronic. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}